-

908 Devices Announces Filing Of Registration Statement For Proposed Initial Public Offering

BOSTON--(BUSINESS WIRE)--908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. 908 Devices intends to list its common stock on NASDAQ under the symbol "MASS."

Cowen and SVB Leerink will act as lead book-running managers for the proposed offering. William Blair and Stifel will be book running managers for the proposed offering.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 833-297-2926, or by email at PostSaleManualRequests@broadridge.com; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02120, telephone: 1-800-808-7525, ext. 6218, or by email at syndicate@svbleerink.com.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About 908 Devices

We are democratizing laboratory mass spectrometry with our simple handheld and desktop devices, addressing critical-to-life applications. Our devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. We are headquartered in the heart of Boston, where we research, design and manufacture innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.

Contacts

Nikki Festa
nfesta@pancomm.com

908 Devices


Release Versions

Contacts

Nikki Festa
nfesta@pancomm.com

More News From 908 Devices

Ohio Attorney General Agencies Deploy 908 Devices Handheld Mass Spec Device to Aid Law Enforcement Cases Involving Illicit Drugs

BOSTON--(BUSINESS WIRE)--MX908 detects and identifies chemical compounds at trace levels onsite and in seconds to minimize opioid exposure risks for field investigators....

908 Devices Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

BOSTON--(BUSINESS WIRE)--908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the closing of its upsized initial public offering of shares of its common stock, with 7,475,000 shares offered and sold by the Company at a public offering price of $20.00 per share, which includes the full exercise of the underwriters’ option to purchase an additional 975,000 shares of common stock from the Company. The shares beg...

908 Devices Announces Pricing of Initial Public Offering

BOSTON--(BUSINESS WIRE)--908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of its upsized initial public offering of shares of its common stock, with 6,500,000 shares being offered by the Company at a public offering price of $20.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 975,000 shares of common stock from the Company at the pu...
Back to Newsroom